Method for serial analysis of gene expression

ABSTRACT

Serial analysis of gene expression, SAGE, a method for the rapid quantitative and qualitative analysis of transcripts is provided. Short defined sequence tags corresponding to expressed genes are isolated and analyzed. Sequencing of over 1,000 defined tags in a short period of time (e.g., hours) reveals a gene expression pattern characteristic of the function of a cell or tissue. Moreover, SAGE is useful as a gene discovery tool for the identification and isolation of novel sequence tags corresponding to novel transcripts and genes.

This application is a divisional application of Ser. No. 09/107,228filed Jun. 30, 1998, now U.S. Pat. No. 6,383,743, which is acontinuation application of Ser. No. 08/544,861, filed Oct. 18, 1995,now U.S. Pat. No. 5,866,330, which is a continuation-in-part applicationof Ser. No. 08/527,154, filed Sep. 12, 1995, now U.S. Pat. No.5,695,937.

This invention was made with support from National Institutes of HealthGrant Nos. CA57345, CA35494, and GM07309. The Government has certainrights in this invention.

FIELD OF THE INVENTION

The present invention relates generally to the field of gene expressionand specifically to a method for the serial analysis of gene expression(SAGE) for the analysis of a large number of transcripts byidentification of a defined region of a transcript which corresponds toa region of an expressed gene.

BACKGROUND OF THE INVENTION

Determination of the genomic sequence of higher organisms, includinghumans, is now a real and attainable goal. However, this analysis onlyrepresents one level of genetic complexity. The ordered and timelyexpression of genes represents another level of complexity equallyimportant to the definition and biology of the organism.

The role of sequencing complementary DNA (cDNA), reverse transcribedfrom mRNA, as part of the human genome project has been debated asproponents of genomic sequencing have argued the difficulty of findingevery mRNA expressed in all tissues, cell types, and developmentalstages and have pointed out that much valuable information from intronicand intergenic regions, including control and regulatory sequences, willbe missed by cDNA sequencing (Report of the Committee on Mapping andSequencing the Human Genome, National Academy Press, Washington, D.C.,1988). Sequencing of transcribed regions of the genome using cDNAlibraries has heretofore been considered unsatisfactory. Libraries ofcDNA are believed to be dominated by repetitive elements, mitochondrialgenes, ribosomal RNA genes, and other nuclear genes comprising common orhousekeeping sequences. It is believed that cDNA libraries do notprovide all sequences corresponding to structural and regulatorypolypeptides or peptides (Putney, et al., Nature, 302:718, 1983).

Another drawback of standard cDNA cloning is that some mRNAs areabundant while others are rare. The cellular quantities of mRNA fromvarious genes can vary by several orders of magnitude.

Techniques based on cDNA subtraction or differential display can bequite useful for comparing gene expression differences between two celltypes (Hedrick, et al., Nature, 308:149, 1984; Liang and Pardee,Science, 257: 967, 1992), but provide only a partial analysis, with nodirect information regarding abundance of messenger RNA. The expressedsequence tag (EST) approach has been shown to be a valuable tool forgene discovery (Adams, et al., Science 252:1656, 1991; Adams, et al.,Nature, 355:632, 1992; Okubo et al., Nature Genetics, 2: 173, 1992), butlike Northern blotting, RNase protection, and reversetranscriptase-polymerase chain reaction (RT-PCR) analysis (Alwine, etal., Proc. Natl. Acad Sci, U.S.A., 74:5350, 1977; Zinn et al., Cell,34:865, 1983; Veres, et al., Science, 237:415, 1987), only evaluates alimited number of genes at a time. In addition, the EST approachpreferably employs nucleotide sequences of 150 base pairs or longer forsimilarity searches and mapping.

Sequence tagged sites (STSs) (Olson, et al., Science, 245:1434, 1989)have also been utilized to identify genomic markers for the physicalmapping of the genome. These short sequences from physically mappedclones represent uniquely identified map positions in the genome. Incontrast, the identification of expressed genes relies on expressedsequence tags which are markers for those genes actually transcribed andexpressed in vivo.

There is a need for an improved method which allows rapid, detailedanalysis of thousands of expressed genes for the investigation of avariety of biological applications, particularly for establishing theoverall pattern of gene expression in different cell types or in thesame cell type under different physiologic or pathologic conditions.Identification of different patterns of expression has severalutilities, including the identification of appropriate therapeutictargets, candidate genes for gene therapy (e.g., gene replacement),tissue typing, forensic identification, mapping locations ofdisease-associated genes, and for the identification of diagnostic andprognostic indicator genes.

SUMMARY OF THE INVENTION

The present invention provides a method for the rapid analysis ofnumerous transcripts in order to identify the overall pattern of geneexpression in different cell types or in the same cell type underdifferent physiologic, developmental or disease conditions. The methodis based on the identification of a short nucleotide sequence tag at adefined position in a messenger RNA. The tag is used to identify thecorresponding transcript and gene from which it was transcribed. Byutilizing dimerized tags, termed a “ditag”, the method of the inventionallows elimination of certain types of bias which might occur duringcloning and/or amplification and possibly during data evaluation.Concatenation of these short nucleotide sequence tags allows theefficient analysis of transcripts in a serial manner by sequencingmultiple tags on a single DNA molecule, for example, a DNA moleculeinserted in a vector or in a single clone.

The method described herein is the serial analysis of gene expression(SAGE), a novel approach which allows the analysis of a large number oftranscripts. To demonstrate this strategy, short cDNA sequence tags weregenerated from mRNA isolated from pancreas, randomly paired to formditags, concatenated, and cloned. Manual sequencing of 1,000 tagsrevealed a gene expression pattern characteristic of pancreaticfunction. Identification of such patterns is important diagnosticallyand therapeutically, for example. Moreover, the use of SAGE as a genediscovery tool was documented by the identification and isolation of newpancreatic transcripts corresponding to novel tags. SAGE provides abroadly applicable means for the quantitative cataloging and comparisonof expressed genes in a variety of normal, developmental, and diseasestates.

BRIEF DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B shows a schematic of SAGE. The first restriction enzyme, oranchoring enzyme, is NlaIII and the second enzyme, or tagging enzyme, isFokI in this example. Sequences represent primer derived sequences, andtranscript derived sequences with “X” and “O” representing nucleotidesof different tags.

FIG. 2 shows a comparison of transcript abundance. Bars represent thepercent abundance as determined by SAGE (dark bars) or hybridizationanalysis (light bars). SAGE quantitations were derived from Table 1 asfollows: TRY1/2 includes the tags for trypsinogen 1 and 2, PROCARindicates tags for procarboxypeptidase A1, CHYMO indicates tags forchymotrypsinogen, and ELA/PRO includes the tags for elastase IIIB andprotease E. Error bars represent the standard deviation determined bytaking the square root of counted events and converting it to a percentabundance (assumed Poisson distribution).

FIGS. 3A-3B shows the results of screening a cDNA library with SAGEtags. P1 and P2 show typical hybridization results obtained with 13 bpoligonucleotides as described in the Examples. P1 and P2 correspond tothe transcripts described in Table 2. Images were obtained using aMolecular Dynamics PhosphorImager and the circle indicates the outlineof the filter membrane to which the recombinant phage were transferredprior to hybridization.

FIG. 4 is a block diagram of a tag code database access system inaccordance with the present invention.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention provides a rapid, quantitative process fordetermining the abundance and nature of transcripts corresponding toexpressed genes. The method, termed serial analysis of gene expression(SAGE), is based on the identification of and characterization ofpartial, defined sequences of transcripts corresponding to genesegments. These defined transcript sequence “tags” are markers for geneswhich are expressed in a cell, a tissue, or an extract, for example.

SAGE is based on several principles. First, a short nucleotide sequencetag (9 to 10 bp) contains sufficient information content to uniquelyidentify a transcript provided it is isolated from a defined positionwithin the transcript. For example, a sequence as short as 9 bp candistinguish 262,144 transcripts (49) given a random nucleotidedistribution at the tag site, whereas estimates suggest that the humangenome encodes about 80,000 to 200,000 transcripts (Fields, et al.,Nature Genetics, 7:345 1994). The size of the tag can be shorter forlower eukaryotes or prokaryotes, for example, where the number oftranscripts encoded by the genome is lower. For example, a tag as shortas 6-7 bp may be sufficient for distinguishing transcripts in yeast.

Second, random dimerization of tags allows a procedure for reducing bias(caused by amplification and/or cloning). Third, concatenation of theseshort sequence tags allows the efficient analysis of transcripts in aserial manner by sequencing multiple tags within a single vector orclone. As with serial communication by computers, wherein information istransmitted as a continuous string of data, serial analysis of thesequence tags requires a means to establish the register and boundariesof each tag. All of these principles may be applied independently, incombination, or in combination with other known methods of sequenceidentification.

In a first embodiment, the invention provides a method for the detectionof gene expression in a particular cell or tissue, or cell extract, forexample, including at a particular developmental stage or in aparticular disease state. The method comprises producing complementarydeoxyribonucleic acid (cDNA) oligonucleotides, isolating a first definednucleotide sequence tag from a first cDNA oligonucleotide and a seconddefined nucleotide sequence tag from a second cDNA oligonucleotide,linking the first tag to a first oligonucleotide linker, wherein thefirst oligonucleotide linker comprises a first sequence forhybridization of an amplification primer and linking the second tag to asecond oligonucleotide linker, wherein the second oligonucleotide linkercomprises a second sequence for hybridization of an amplificationprimer, and determining the nucleotide sequence of the tag(s), whereinthe tag(s) correspond to an expressed gene.

FIG. 1 shows a schematic representation of the analysis of messenger RNA(mRNA) using SAGE as described in the method of the invention. mRNA isisolated from a cell or tissue of interest for in vitro synthesis of adouble-stranded DNA sequence by reverse transcription of the mRNA. Thedouble-stranded DNA complement of mRNA formed is referred to ascomplementary (cDNA).

The term “oligonucleotide” as used herein refers to primers or oligomerfragments comprised of two or more deoxyribonucleotides orribonucleotides, preferably more than three. The exact size will dependon many factors, which in turn depend on the ultimate function or use ofthe oligonucleotide.

The method further includes ligating the first tag linked to the firstoligonucleotide linker to the second tag linked to the secondoligonucleotide linker and forming a “ditag”. Each ditag represents twodefined nucleotide sequences of at least one transcript, representativeof at least one gene. Typically, a ditag represents two transcripts fromtwo distinct genes. The presence of a defined cDNA tag within the ditagis indicative of expression of a gene having a sequence of that tag.

The analysis of ditags, formed prior to any amplification step, providesa means to eliminate potential distortions introduced by amplification,e.g., PCR. The pairing of tags for the formation of ditags is a randomevent. The number of different tags is expected to be large, therefore,the probability of any two tags being coupled in the same ditag issmall, even for abundant transcripts. Therefore, repeated ditagspotentially produced by biased standard amplification and/or cloningmethods are excluded from analysis by the method of the invention.

The term “defined” nucleotide sequence, or “defined” nucleotide sequencetag, refers to a nucleotide sequence derived from either the 5′ or 3′terminus of a transcript. The sequence is defined by cleavage with afirst restriction endonuclease, and represents nucleotides either 5′ or3′ of the first restriction endonuclease site, depending on whichterminus is used for capture (e.g., 3′ when oligo-dT is used for captureas described herein).

As used herein, the terms “restriction endonucleases” and “restrictionenzymes” refer to bacterial enzymes which bind to a specificdouble-stranded DNA sequence termed a recognition site or recognitionnucleotide sequence, and cut double-stranded DNA at or near the specificrecognition site.

The first endonuclease, termed “anchoring enzyme” or “AE” in FIG. 1, isselected by its ability to cleave a transcript at least one time andtherefore produce a defined sequence tag from either the 5′ or 3′ end ofa transcript. Preferably, a restriction endonuclease having at least onerecognition site and therefore having the ability to cleave a majorityof cDNAs is utilized. For example, as illustrated herein, enzymes whichhave a 4 base pair recognition site are expected to cleave every 256base pairs (4⁴) on average while most transcripts are considerablylarger. Restriction endonucleases which recognize a 4 base pair siteinclude NlaIII, as exemplified in the EXAMPLES of the present invention.Other similar endonucleases having at least one recognition site withina DNA molecule (e.g., cDNA) will be known to those of skill in the art(see for example, Current Protocols in Molecular Biology, Vol. 2, 1995,Ed. Ausubel, et al., Greene Publish. Assoc. & Wiley Interscience, Unit3.1.15; New England Biolabs Catalog, 1995).

After cleavage with the anchoring enzyme, the most 5′ or 3′ region ofthe cleaved cDNA can then be isolated by binding to a capture medium.For example, as illustrated in the present EXAMPLES, streptavidin beadsare used to isolate the defined 3′ nucleotide sequence tag when theoligo dT primer for cDNA synthesis is biotinylated. In this example,cleavage with the first or anchoring enzyme provides a unique site oneach transcript which corresponds to the restriction site locatedclosest to the poly-A tail. Likewise, the 5′ cap of a transcript (thecDNA) can be utilized for labeling or binding a capture means forisolation of a 5′ defined nucleotide sequence tag. Those of skill in theart will know other similar capture systems (e.g., biotin/streptavidin,digoxigenin/anti-digoxigenin) for isolation of the defined sequence tagas described herein.

The invention is not limited to use of a single “anchoring” or firstrestriction endonuclease. It may be desirable to perform the method ofthe invention sequentially, using different enzymes on separate samplesof a preparation, in order to identify a complete pattern oftranscription for a cell or tissue. In addition, the use of more thanone anchoring enzyme provides confirmation of the expression patternobtained from the first anchoring enzyme. Therefore, it is alsoenvisioned that the first or anchoring endonuclease may rarely cut cDNAsuch that few or no cDNA representing abundant transcripts are cleaved.Thus, transcripts which are cleaved represent “unique” transcripts.Restriction enzymes that have a 7-8 bp recognition site for example,would be enzymes that would rarely cut cDNA. Similarly, more than onetagging enzyme, described below, can be utilized in order to identify acomplete pattern of transcription.

The term “isolated” as used herein includes polynucleotidessubstantially free of other nucleic acids, proteins, lipids,carbohydrates or other materials with which it is naturally associated.cDNA is not naturally occurring as such, but rather is obtained viamanipulation of a partially purified naturally occurring mRNA. Isolationof a defined sequence tag refers to the purification of the 5′ or 3′ tagfrom other cleaved cDNA.

In one embodiment, the isolated defined nucleotide sequence tags areseparated into two pools of cDNA, when the linkers have differentsequences. Each pool is ligated via the anchoring, or first restrictionendonuclease site to one of two linkers. When the linkers have the samesequence, it is not necessary to separate the tags into pools. The firstoligonucleotide linker comprises a first sequence for hybridization ofan amplification primer and the second oligonucleotide linker comprisesa second sequence for hybridization of an amplification primer. Inaddition, the linkers further comprise a second restriction endonucleasesite, also termed the “tagging enzyme” or “TE”. The method of theinvention does not require, but preferably comprises amplifying theditag oligonucleotide after ligation.

The second restriction endonuclease cleaves at a site distant from oroutside of the recognition site. For example, the second restrictionendonuclease can be a type IIS restriction enzyme. Type IIS restrictionendonucleases cleave at a defined distance up to 20 bp away from theirasymmetric recognition sites (Szybalski, W., Gene, 40:169, 1985).Examples of type IIS restriction endonucleases include BsmFI and FokI.Other similar enzymes will be known to those of skill in the art (see,Current Protocols in Molecular Biology, supra).

The first and second “linkers” which are ligated to the definednucleotide sequence tags are oligonucleotides having the same ordifferent nucleotide sequences. For example, the linkers illustrated inthe Examples of the present invention include linkers having differentsequences:

5′- TTTTACCAGCTTATTCAATTCGGTCCTCTCGCACAGGGACATG -3′ (SEQ ID NO:1) 3′- ATGGTCGAATAAGTTAAGCCAGGAGAGCGTGTCCCT -5′ (SEQ ID NO:2) and 5′-TTTTTGTAGACATTCTAGTATCTCGTCAAGTCGGAAGGGACATG -3′ (SEQ ID NO:3) 3′- AACATCTGTAAGATCATAGAGCAGTTCAGCCTTCCCT -5′ (SEQ ID NO:4),

(SEQ ID NO:4), wherein A is a dideoxy nucleotide (e.g., dideoxy A).Other similar linkers can be utilized in the method of the invention;those of skill in the art can design such alternate linkers.

The linkers are designed so that cleavage of the ligation products withthe second restriction enzyme, or tagging enzyme, results in release ofthe linker having a defined nucleotide sequence tag (e.g., 3′ of therestriction endonuclease cleavage site as exemplified herein). Thedefined nucleotide sequence tag may be from about 6 to 30 base pairs.Preferably, the tag is about 9 to 11 base pairs. Therefore, a ditag isfrom about 12 to 60 base pairs, and preferably from 18 to 22 base pairs.

The pool of defined tags ligated to linkers having the same sequence, orthe two pools of defined nucleotide sequence tags ligated to linkershaving different nucleotide sequences, are randomly ligated to eachother “tail to tail”. The portion of the cDNA tag furthest from thelinker is referred to as the “tail”. As illustrated in FIG. 1, theligated tag pair, or ditag, has a first restriction endonuclease siteupstream (5′) and a first restriction endonuclease site downstream (3′)of the ditag; a second restriction endonuclease cleavage site upstreamand downstream of the ditag, and a linker oligonucleotide containingboth a second restriction enzyme recognition site and an amplificationprimer hybridization site upstream and downstream of the ditag. In otherwords, the ditag is flanked by the first restriction endonuclease site,the second restriction endonuclease cleavage site and the linkers,respectively.

The ditag can be amplified by utilizing primers which specificallyhybridize to one strand of each linker. Preferably, the amplification isperformed by standard polymerase chain reaction (PCR) methods asdescribed (U.S. Pat. No. 4,683,195). Alternatively, the ditags can beamplified by cloning in prokaryotic-compatible vectors or by otheramplification methods known to those of skill in the art.

The term “primer” as used herein refers to an oligonucleotide, whetheroccurring naturally or produced synthetically, which is capable ofacting as a point of initiation of synthesis when placed underconditions in which synthesis of primer extension product which iscomplementary to a nucleic acid strand is induced, i.e., in the presenceof nucleotides and an agent for polymerization such as DNA polymeraseand at a suitable temperature and pH. The primer is preferably singlestranded for maximum efficiency in amplification. Preferably, the primeris an oligodeoxy ribonucleotide. The primer must be sufficiently long toprime the synthesis of extension products in the presence of the agentfor polymerization. The exact lengths of the primers will depend on manyfactors, including temperature and source of primer.

The primers herein are selected to be “substantially” complementary tothe different strands of each specific sequence to be amplified. Thismeans that the primers must be sufficiently complementary to hybridizewith their respective strands. Therefore, the primer sequence need notreflect the exact sequence of the template. In the present invention,the primers are substantially complementary to the oligonucleotidelinkers.

Primers useful for amplification of the linkers exemplified herein asSEQ ID NO: 1-4 include 5′-CCAGCTTATTCAATTCGGTCC-3′ (SEQ ID NO:5) and5′-GTAGACATTCTAGTATCTCGT-3′ (SEQ ID NO:6). Those of skill in the art canprepare similar primers for amplification based on the nucleotidesequence of the linkers without undue experimentation.

Cleavage of the amplified PCR product with the first restrictionendonuclease allows isolation of ditags which can be concatenated byligation. After ligation, it may be desirable to clone the concatemers,although it is not required in the method of the invention. Analysis ofthe ditags or concatemers, whether or not amplification was performed,is by standard sequencing methods. Concatemers generally consist ofabout 2 to 200 ditags and preferably from about 8 to 20 ditags. Whilethese are preferred concatemers, it will be apparent that the number ofditags which can be concatenated will depend on the length of theindividual tags and can be readily determined by those of skill in theart without undue experimentation. After formation of concatemers,multiple tags can be cloned into a vector for sequence analysis, oralternatively, ditags or concatemers can be directly sequenced withoutcloning by methods known to those of skill in the art.

Among the standard procedures for cloning the defined nucleotidesequence tags of the invention is insertion of the tags into vectorssuch as plasmids or phage. The ditag or concatemers of ditags producedby the method described herein are cloned into recombinant vectors forfurther analysis, e.g., sequence analysis, plaque/plasmid hybridizationusing the tags as probes, by methods known to those of skill in the art.

The term “recombinant vector” refers to a plasmid, virus or othervehicle known in the art that has been manipulated by insertion orincorporation of the ditag genetic sequences. Such vectors contain apromoter sequence which facilitates the efficient transcription of the amarker genetic sequence for example. The vector typically contains anorigin of replication, a promoter, as well as specific genes which allowphenotypic selection of the transformed cells. Vectors suitable for usein the present invention include for example, pBlueScript (Stratagene,La Jolla, Calif.); pBC, pSL301 (Invitrogen) and other similar vectorsknown to those of skill in the art. Preferably, the ditags orconcatemers thereof are ligated into a vector for sequencing purposes.

Vectors in which the ditags are cloned can be transferred into asuitable host cell. “Host cells” are cells in which a vector can bepropagated and its DNA expressed. The term also includes any progeny ofthe subject host cell. It is understood that all progeny may not beidentical to the parental cell since there may be mutations that occurduring replication. However, such progeny are included when the term“host cell” is used. Methods of stable transfer, meaning that theforeign DNA is continuously maintained in the host, are known in theart.

Transformation of a host cell with a vector containing ditag(s) may becarried out by conventional techniques as are well known to thoseskilled in the art. Where the host is prokaryotic, such as E. coli,competent cells which are capable of DNA uptake can be prepared fromcells harvested after exponential growth phase and subsequently treatedby the CaCl₂ method using procedures well known in the art.Alternatively, MgCl₂ or RbCl can be used. Transformation can also beperformed by electroporation or other commonly used methods in the art.

The ditags present in a particular clone can be sequenced by standardmethods (see for example, Current Protocols in Molecular Biology, supra,Unit 7) either manually or using automated methods.

In another embodiment, the present invention provides a kit useful fordetection of gene expression wherein the presence of a definednucleotide tag or ditag is indicative of expression of a gene having asequence of the tag, the kit comprising one or more containerscomprising a first container containing a first oligonucleotide linkerhaving a first sequence useful hybridization of an amplification primer;a second container containing a second oligonucleotide linker having asecond oligonucleotide linker having a second sequence usefulhybridization of an amplification primer, wherein the linkers furthercomprise a restriction endonuclease site for cleavage of DNA at a sitedistant from the restriction endonuclease recognition site; and a thirdand fourth container having a nucleic acid primers for hybridization tothe first and second unique sequence of the linker. It is apparent thatif the oligonucleotide linkers comprise the same nucleotide sequence,only one container containing linkers is necessary in the kit of theinvention.

In yet another embodiment, the invention provides an oligonucleotidecomposition having at least two defined nucleotide sequence tags,wherein at least one of the sequence tags corresponds to at least oneexpressed gene. The composition consists of about 1 to 200 ditags, andpreferably about 8 to 20 ditags. Such compositions are useful for theanalysis of gene expression by identifying the defined nucleotidesequence tag corresponding to an expressed gene in a cell, tissue orcell extract, for example.

It is envisioned that the identification of differentially expressedgenes using the SAGE technique of the invention can be used incombination with other genomics techniques. For example, individualtags, and preferably ditags, can be hybridized with oligonucleotidesimmobilized on a solid support (e.g., nitrocellulose filter, glassslide, silicon chip). Such techniques include “parallel sequenceanalysis” or PSA, as described below. The sequence of the ditags formedby the method of the invention can also be determined using limitingdilutions by methods including clonal sequencing (CS).

Briefly, PSA is performed after ditag preparation, wherein theoligonucleotide sequences to which the ditags are hybridized arepreferably unlabeled and the ditag is preferably detectably labeled.Alternatively, the oligonucleotide can be labeled rather than the ditag.The ditags can be detectably labeled, for example, with a radioisotope,a fluorescent compound, a bioluminescent compound, a chemi-luminescentcompound, a metal chelator, or an enzyme. Those of ordinary skill in theart will know of other suitable labels for binding to the ditag, or willbe able to ascertain such, using routine experimentation. For example,PCR can be performed with labeled (e.g., fluorescein tagged) primers.Preferably, the ditag contains a fluorescent end label.

The labeled or unlabeled ditags are separated into single-strandedmolecules which are preferably serially diluted and added to a solidsupport (e.g., a silicon chip as described by Fodor, et al., Science,251:767, 1991) containing oligonucleotides representing, for example,every possible permutation of a 10-mer (e.g., in each grid of a chip).The solid support is then used to determine differential expression ofthe tags contained within that support (e.g., on a grid on a chip) byhybridization of the oligonucleotides on the solid support with tagsproduced from cells under different conditions (e.g., different stage ofdevelopment, growth of cells in the absence and presence of a growthfactor, normal versus transformed cells, comparison of different tissueexpression, etc). In the case of fluoresceinated end labeled ditags,analysis of fluorescence is indicative of hybridization to a particular10-mer. When the immobilized oligonucleotide is fluoresceinated forexample, a loss of fluorescence due to quenching (by the proximity ofthe hybridized ditag to the labeled oligo) is observed and is analyzedfor the pattern of gene expression. An illustrative example of themethod is shown in Example 4 herein.

The SAGE method of the invention is also useful for clonal sequencing,similar to limiting dilution techniques used in cloning of cell lines.For example, ditags or concatemers thereof, are diluted and added toindividual receptacles such that each receptacle contains less than oneDNA molecule per receptacle. DNA in each receptacle is amplified andsequenced by standard methods known in the art, including massspectroscopy. Assessment of differential expression is performed asdescribed above for SAGE.

Those of skill in the art can readily determine other methods ofanalysis for ditags or individual tags produced by SAGE as described inthe present invention, without resorting to undue experimentation.

The concept of deriving a defined tag from a sequence in accordance withthe present invention is useful in matching tags of samples to asequence database. In the preferred embodiment, a computer method isused to match a sample sequence with known sequences.

In one embodiment, a sequence tag for a sample is compared tocorresponding information in a sequence database to identify knownsequences that match the sample sequence. One or more tags can bedetermined for each sequence in the sequence database as the N basepairs adjacent to each anchoring enzyme site within the sequence.However, in the preferred embodiment, only the first anchoring enzymesite from the 3′ end is used to determine a tag. In the preferredembodiment, the adjacent base pairs defining a tag are on the 3′ side ofthe anchoring enzyme site, and N is preferably 9.

A linear search through such a database may be used. However, in thepreferred embodiment, a sequence tag from a sample is converted to aunique numeric representation by converting each base pair (A, C, G, orT) of an N-base tag to a number or “tag code” (e.g., A=0, C=1, G=2, T=3,or any other suitable mapping). A tag is determined for each sequence ofa sequence database as described above, and the tag is converted to atag code in a similar manner. In the preferred embodiment, a set of tagcodes for a sequence database is stored in a pointer file. The tag codefor a sample sequence is compared to the tag codes in the pointer fileto determine the location in the sequence database of the sequencecorresponding to the sample tag code. (Multiple corresponding sequencesmay exist if the sequence database has redundancies).

FIG. 4 is a block diagram of a tag code database access system inaccordance with the present invention. A sequence database 10 (e.g., theHuman Genome Sequence Database) is processed as described above, suchthat each sequence has a tag code determined and stored in a pointerfile 12. A sample tag code X for a sample is determined as describedabove, and stored within a memory location 14 of a computer. The sampletag code X is compared to the pointer file 12 for a matching sequencetag code. If a match is found, a pointer associated with the matchingsequence tag code is used to access the corresponding sequence in thesequence database 10.

The pointer file 12 may be in any of several formats. In one format,each entry of the pointer file 12 comprises a tag code and a pointer toa corresponding record in the sequence database 12. The sample tag codeX can be compared to sequence tag codes in a linear search.Alternatively, the sequence tag codes can be sorted and a binary searchused. As another alternative, the sequence tag codes can be structuredin a hierarchical tree structure (e.g., a B-tree), or as a singly ordoubly linked list, or in any other conveniently searchable datastructure or format.

In the preferred embodiment, each entry of the pointer file 12 comprisesonly a pointer to a corresponding record in the sequence database 10. Inbuilding the pointer file 12, each sequence tag code is assigned to anentry position in the pointer file 12 corresponding to the value of thetag code. For example, if a sequence tag code was “1043”, a pointer tothe corresponding record in the sequence database 10 would be stored inentry #1043 of the pointer file 12. The value of a sample tag code X canbe used to directly address the location in the pointer file 12 thatcorresponds to the sample tag code X, and thus rapidly access thepointer stored in that location in order to address the sequencedatabase 10.

Because only four values are needed to represent all possible basepairs, using binary coded decimal (BCD) numbers for tag codes inconjunction with the preferred pointer file 12 structure leads to a“sparse” pointer file 12 that wastes memory or storage space.Accordingly, the present invention transforms each tag code to numberbase 4 (i.e., 2 bits per code digit), in known fashion, resulting in acompact pointer file 12 structure. For example, for tag sequence “AGCT”,with A=00₂, C=01₂, G=10₂, T=11₂, the base four representation in binarywould be “00011011”. In contrast, the BCD representation would be“00000000 00000001 00000010 000000011”. Of course, it should beunderstood that other mappings of base pairs to codes would provideequivalent function.

The concept of deriving a defined tag from a sample sequence inaccordance with the present invention is also useful in comparingdifferent samples for similarity. In the preferred embodiment, acomputer method is used to match sequence tags from different samples.For example, in comparing materials having a large number of sequences(e.g., tissue), the frequency of occurrence of the various tags in afirst sample can be mapped out as tag codes stored in a distribution orhistogram-type data structure. For example, a table structured similarto pointer file 12 in FIG. 4 can be used where each entry comprises afrequency of occurrence value. Thereafter, the various tags in a secondsample can be generated, converted to tag codes, and compared to thetable by directly addressing table entries with the tag code. A countcan be kept of the number of matches found, as well as the location ofthe matches, for output in text or graphic form on an output device,and/or for storage in a data storage system for later use.

The tag comparison aspects of the invention may be implemented inhardware or software, or a combination of both. Preferably, theseaspects of the invention are implemented in computer programs executingon a programmable computer comprising a processor, a data storage system(including volatile and non-volatile memory and/or storage elements), atleast one input device, and at least one output device. Data inputthrough one or more input devices for temporary or permanent storage inthe data storage system includes sequences, and may include previouslygenerated tags and tag codes for known and/or unknown sequences. Programcode is applied to the input data to perform the functions describedabove and generate output information. The output information is appliedto one or more output devices, in known fashion.

Each such computer program is preferably stored on a storage media ordevice (e.g., ROM or magnetic diskette) readable by a general or specialpurpose programmable computer, for configuring and operating thecomputer when the storage media or device is read by the computer toperform the procedures described herein. The inventive system may alsobe considered to be implemented as a computer-readable storage medium,configured with a computer program, where the storage medium soconfigured causes a computer to operate in a specific and predefinedmanner to perform the functions described herein.

The following examples are intended to illustrate but not limit theinvention. While they are typical of those that might be used, otherprocedures known to those skilled in the art may alternatively be used.

EXAMPLES

For exemplary purposes, the SAGE method of the invention was used tocharacterized gene expression in the human pancreas. NlaIII was utilizedas the first restriction endonuclease, or anchoring enzyme, and BsmFI asthe second restriction endonuclease, or tagging enzyme, yielding a 9 bptag (BsmFI was predicted to cleave the complementary strand 14 bp 3′ tothe recognition site GGGAC and to yield a 4 bp 5′ overhang (New EnglandBioLabs). Overlapping the BsmFI and NlaIII (CATG) sites as indicated(GGGACATG) would be predicted to result in a 11 bp tag. However,analysis suggested that under the cleavage conditions used (37° C.),BsmFI often cleaved closer to its recognition site leaving a minimum of12 bp 3′ of its recognition site. Therefore, only the 9 bp closest tothe anchoring enzyme site was used for analysis of tags. Cleavage at 65°C. results in a more consistent 11 bp tag.

Computer analysis of human transcripts from Gen Bank indicated thatgreater than 95% of tags of 9 bp in length were likely to be unique andthat inclusion of two additional bases provided little additionalresolution. Human sequences (84,300) were extracted from the GenBank 87database using the Findseq program provided on the IntelliGeneticsBionet on-line service. All further analysis was performed with a SAGEprogram group written in Microsoft Visual Basic for the MicrosoftWindows operating system. The SAGE database analysis program was set toinclude only sequences noted as “RNA” in the locus description and toexclude entries noted as “EST”, resulting in a reduction to 13,241sequences. Analysis of this subset of sequences using NlaIII asanchoring Enzyme indicated that 4,127 nine bp tags were unique while1,511 tags were found in more than one entry. Nucleotide comparison of arandomly chosen subset (100) of the latter entries indicated that atleast 83% were due to redundant data base entries for the same gene orhighly related genes (>95% identity over at least 250 bp). Thissuggested that 5381 of the 9 bp tags (95.5%) were unique to a transcriptor highly conserved transcript family. Likewise, analysis of the samesubset of GenBank with an 11 bp tag resulted only in a 6% decrease inrepeated tags (1511 to 1425) instead of the 94% decrease expected if therepeated tags were due to unrelated transcripts.

Example 1

As outlined above, mRNA from human pancreas was used to generate ditags.Briefly, five ug mRNA from total pancreas (Clontech) was converted todouble stranded cDNA using a BRL cDNA synthesis kit following themanufacturer's protocol, using the primer biotin-5′T₁₈-3′. The cDNA wasthen cleaved with NlaIII and the 3′ restriction fragments isolated bybinding to magnetic streptavidin beads (Dynal). The bound DNA wasdivided into two pools, and one of the following linkers ligated to eachpool:

5′- TTTTACCAGCTTATTCAATTCGGTCCTCTCGCACAGGGACATG -3′ (SEQ ID NO:1 and 2)3′- A TGGTCGAATAAGTTAAGCCAGGAGAGCGTGTCCCT -5′ 5′-TTTTTGTAGACATTCTAGTATCTCGTCAAGTCGGAAGGGACATG -3′ (SEQ ID NO:3 and 4),3′- A ACATCTGTAAGATCATAGAGCAGTTCAGCCTTCCCT -5′

where A is a dideoxy nucleotide (e.g., dideoxy A).

After extensive washing to remove unligated linkers, the linkers andadjacent tags were released by cleavage with BsmFI. The resultingoverhangs were filled in with T4 polymerase and the pools combined andligated to each other. The desired ligation product was then amplifiedfor 25 cycles using 5′-CCAGCTTATTCAATTCGGTCC-3′ and5′-GTAGACATTCTAGTATCTCGT-3′ (SEQ ID NO:5 and 6, respectively) asprimers. The PCR reaction was then analyzed by polyacrylamide gelelectrophoresis and the desired product excised. An additional 15 cyclesof PCR were then performed to generate sufficient product for efficientligation and cloning.

The PCR ditag products were cleaved with NlaIII and the band containingthe ditags was excised and self-ligated. After ligation, theconcatenated ditags were separated by polyacrylamide gel electrophoresisand products greater than 200 bp were excised. These products werecloned into the SphI site of pSL301 (Invitrogen). Colonies were screenedfor inserts by PCR using T7 and T3 sequences outside the cloning site asprimers. Clones containing at least 10 tags (range 10 to 50 tags) wereidentified by PCR amplification and manually sequenced as described (DelSal, et al., Biotechniques 7:514, 1989) using5′-GACGTCGACCTGAGGTAATTATAACC-3′ (SEQ ID NO:7) as primer. Sequence fileswere analyzed using the SAGE software group which identifies theanchoring enzyme site with the proper spacing and extracts the twointervening tags and records them in a database. The 1,000 tags werederived from 413 unique ditags and 87 repeated ditags. The latter wereonly counted once to eliminate potential PCR bias of the quantitation.The function of SAGE software is merely to optimize the search for genesequences.

Table 1 shows analysis of the first 1,000 tags. Sixteen percent wereeliminated because they either had sequence ambiguities or were derivedfrom linker sequences. The remaining 840 tags included 351 tags thatoccurred once and 77 tags that were found multiple times. Nine of theten most abundant tags matched at least one entry in GenBank R87. Theremaining tag was subsequently shown to be derived from amylase. All tentranscripts were derived from genes of known pancreatic function andtheir prevalence was consistent with previous analyses of pancreatic RNAusing conventional approaches (Han, et al., Proc. Natl. Acad. Sci.U.S.A. 83:110, 1986; Takeda, et al., Hum. Mol. Gen., 2:1793, 1993).

TABLE 1 Pancreatic SAGE Tags TAG Gene N Percent GAGCACACCProcarboxypeptidase A1 (X67318) 64  7.6 TTCTGTGTG Pancreatic Trypsinogen2 (M27602) 46  5.5 GAACACAAA Chymotrypsinogen (M24400) 37  4.4 TCAGGGTGAPancreatic Trypsin 1 (M22612) 31  3.7 GCGTGACCA Elastase IIIB (M18692)20  2.4 GTGTGTGCT Protease E (D00306) 16  1.9 TCATTGGCC PancreaticLipase (M93285) 16  1.9 CCAGAGAGT Procarboxypeptidase B (M81057) 14  1.7TCCTCAAAA No Match, See Table 2, P1 14  1.7 AGCCTTGGT Bile SaltStimulated Lipase (X54457) 12  1.4 GTGTGCGCT No Match 11  1.3 TGCGAGACCNo Match, See Table 2, P2 9 1.1 GTGAAACCC 21 Alu entries 8 1.0 GGTGACTCTNo Match 8 1.0 AAGGTAACA Secretary Trypsin Inhibitor (M11949) 6 0.7TCCCCTGTG No Match 5 0.6 GTGACCACG No Match 5 0.6 CCTGTAATC M91159,M29366,11 Alu entries 5 0.6 CACGTTGGA No Match 5 0.6 AGCCCTACA No Match5 0.6 AGCACCTCC Elongation Factor 2 (Z11692) 5 0.6 ACGCAGGGA No Match,See Table 2, P3 5 0.6 AATTGAAGA No Match, See Table 2, P4 5 0.6TTCTGTGGG No Match 4 0.5 TTCATACAC No Match 4 0.5 GTGGCAGGCNF-kB(X61499), Alu entry (S94541) 4 0.5 GTAAAACCC TNF receptor 11(M55994), Alu entry(X01448) 4 0.5 GAACACACA No Match 4 0.5 CCTGGGAAGPancreatic Mucin (J05582) 4 0.5 CCCATCGTC Mitochondrial CytC Oxidase(X15759) 4 0.5 (SEQ ID NO:8-37) Summary SAGE tags Greater than threetimes 380   45.2  Occurring Three times (15 × 3 =) 45  5.4 Two times (32× 2 =) 64  7.6 One time 351   41.8  Total SAGE Tags 840   100.0  

“Tag” indicates the 9 bp sequence unique to each tag, adjacent to the 4bp anchoring NlaIII site. “N” and “Percent” indicates the number oftimes the tag was identified and its frequency, respectively. “Gene”indicates the accession number and description of GenBank R87 entriesfound to match the indicated tag using the SAGE software group with thefollowing exceptions. When multiple entries were identified because ofduplicated entries, only one entry is listed. In the cases ofchymotrypsinogen, and trypsinogen 1, other genes were identified thatwere predicted to contain the same tags, but subsequent hybridizationand sequence analysis identified the listed genes as the source of thetags. “Alu entry” indicates a match with a GenBank entry for atranscript that contained at least one copy of the alu consensussequence (Deininger, et al., J. Mol. Biol., 151:17, 1981).

Example 2

The quantitative nature of SAGE was evaluated by construction of anoligo-dT primed pancreatic cDNA library which was screened with cDNAprobes for trypsinogen 1/2, procarboxpeptidase A1, chymotrypsinogen andelastase IIIB/protease E. Pancreatic mRNA from the same preparation asused for SAGE in Example 1 was used to construct a cDNA library in theZAP Express vector using the ZAP Express cDNA Synthesis kit followingthe manufacturer's protocol (Stratagene). Analysis of 15 randomlyselected clones indicated that 100% contained cDNA inserts. Platescontaining 250 to 500 plaques were hybridized as previously described(Ruppert, et al., Mol. Cell. Biol. 8:3104, 1988). cDNA probes fortrypsinogen 1, trypsinogen 2, procarboxypeptidase A1, chymotrypsinogen,and elastase IIIB were derived by RT-PCR from pancreas RNA. Thetrypsinogen 1 and 2 probes were 93% identical and hybridized to the sameplaques under the conditions used. Likewise, the elastase IIIB probe andprotease E probe were over 95% identical and hybridized to the sameplaques.

The relative abundance of the SAGE tags for these transcripts was inexcellent agreement with the results obtained with library screening(FIG. 2). Furthermore, whereas neither trypsinogen 1 and 2 nor elastaseIIIB and protease E could be distinguished by the cDNA probes used toscreen the library, all four transcripts could readily be distinguishedon the basis of their SAGE tags (Table 1).

Example 3

In addition to providing quantitative information on the abundance ofknown transcripts, SAGE could be used to identify novel expressed genes.While for the purposes of the SAGE analysis in this example, only the 9bp sequence unique to each transcript was considered, each SAGE tagdefined a 13 bp sequence composed of the anchoring enzyme (4 bp) siteplus the 9 bp tag. To illustrate this potential, 13 bp oligonucleotideswere used to isolate the transcripts corresponding to four unassignedtags (P1 to P4), that is, tags without corresponding entries fromGenBank R87 (Table 1). In each of the four cases, it was possible toisolate multiple cDNA clones for the tag by simply screening thepancreatic cDNA library using 13 bp oligonucleotide as hybridizationprobe (examples in FIG. 3).

Plates containing 250 to 2,000 plaques were hybridized tooligonucleotide probes using the same conditions previously describedfor standard probes except that the hybridization temperature wasreduced to room temperature. Washes were performed in 6×SSC/0.1% SDS for30 minutes at room temperature. The probes consisted of 13 bpoligonucleotides which were labeled with γ³²P-ATP using T4polynucleotide kinase. In each case, sequencing of the derived clonesidentified the correct SAGE tag at the predicted 3′ end of theidentified transcript. The abundance of plaques identified byhybridization with the 13-mers was in good agreement with that predictedby SAGE (Table 2). Tags P1 and P2 were found to correspond to amylaseand preprocarboxypeptidase A2, respectively. No entry forpreprocarboxypeptidase A2 and only a truncated entry for amylase waspresent in GenBank R87, thus accounting for their unassignedcharacterization. Tag P3 did not match any genes of known function inGenBank but did match numerous EST's, providing further evidence that itrepresented a bona fide transcript. The cDNA identified by P4 showed nosignificant homology, suggesting that it represented a previouslyuncharacterized pancreatic transcript.

TABLE 2 Characterization of Unassigned SAGE Tags Abundance SAGE TAG SAGE13mer Hyb Tag Description P1 TCCTCAAAA (SEQ ID NO:38) 1.7% 1.5%(6/388) + 3′ end of Pancreatic Amylase (M28443) P2 TGCGAGACC (SEQ IDNO:39) 1.1% 1.2% (43/3700) + 3′ end of Preprocarboxypeptidase A2(U19977) P3 ACGCAGGGA (SEQ ID NO:40) 0.6% 0.2% (5/2772) + EST match(R45808) P4 AATTGAAGA (SEQ ID NO:41) 0.6% 0.4% (6/1587) + no match

“Tag” and “SAGE Abundance” are described in Table 1; “13mer Hyb”indicates the results obtained by screening a cDNA library with a 13mer,as described above. The number of positive plaques divided by the totalplaques screened is indicated in parentheses following the percentabundance. A positive in the “SAGE Tag” column indicates that theexpected SAGE tag sequence was identified near the 3′ end of isolatedclones. “Description” indicates the results of BLAST searches of thedaily updated GenBank entries at NCBI a of Jun. 9, 1995 (Altschul, etal., J. Mol. Biol., 215:403, 1990). A description and Accession numberare given for the most significant matches. P 1 was found to match atruncated entry for amylase, and P2 was found to match an unpublishedentry for preprocarboxypeptidase A2 which was entered after GenBank R87.

Example 4

Ditags produced by SAGE can be analyzed by PSA or CS. as described inthe specification. In a preferred embodiment of PSA, the following stepsare carried out with ditags:

Ditags are prepared, amplified and cleaved with the anchoring enzyme asdescribed in the previous examples.

OOOOOOOOOOXXXXXXXXXXCATG-3′ 3′-GTACOOOOOOOOOOXXXXXXXXXX

Four-base oligomers containing an identifier (e.g., a fluorescentmoiety, FL) are prepared that are complementary to the overhangs, forexample, FL-CATG. The FL-CATG oligomers (in excess) are ligated to theditags as shown below:

5′-FL-CATGOOOOOOOOOOXXXXXXXXXXCATG      GTACOOOOOOOOOOXXXXXXXXXXGTAC-FL-5′

The ditags are then purified and melted to yield single-stranded DNAshaving the formula:

5′-FL-CATGOOOOOOOOOOOXXXXXXXXXXCATG andGTACOOOOOOOOOOXXXXXXXXXXGTAC-FL-5′,

for example. The mixture of single-stranded DNAs is preferably seriallydiluted. Each serial dilution is hybridized under appropriate stringencyconditions with solid matrices containing gridded single-strandedoligonucleotides; all of the oligonucleotides contain a half-site of theanchoring enzyme cleavage sequence. In the example used herein, theoligonucleotide sequences contain a CATG sequence at the 5′ end:

CATGOOOOOOOOOO, CATGXXXXXXXXXX, etc. (or alternatively a CATG sequenceat the 3′ end: OOOOOOOOOCATG)

The matrices can be constructed of any material known in the art and theoligonucleotide-bearing chips can be generated by any procedure known inthe art, e.g. silicon chips containing oligonucleotides prepared by theVLSIP procedure (Fodor et al., supra).

The oligonucleotide-bearing matrices are evaluated for the presence orabsence of a fluorescent ditag at each position in the grid.

In a preferred embodiment, there are 4¹⁰, or 1,048,576, oligonucleotideson the grid(s) of the general sequence CATGOOOOOOOOOO, such that everypossible 10-base sequence is represented 3′ to the CATG, where CATG isused as an example of an anchoring enzyme half site that iscomplementary to the anchoring enzyme half site at the 3′ end of theditag. Since there are estimated to be no more than 100,000 to 200,000different expressed genes in the human genome, there are enougholigonucleotide sequences to detect all of the possible sequencesadjacent to the 3′-most anchoring enzyme site observed in the cDNAs fromthe expressed genes in the human genome.

In yet another embodiment, structures as described above containing thesequences

PRIMER A- GGAGCATG (X)₁₀ (O)₁₀ CATGCATCC- PRIMER B PRIMER A- CCTCGTAC(X)₁₀ (O)₁₀ GTACGTAGG- PRIMER B

are amplified, cleaved with tagging enzyme and thereafter with anchoringenzyme to generate tag complements of the structure:

(O)₁₀ CATG-3′, which can then be labeled, melted, and hybridized witholigonucleotides on a solid support.

A determination is made of differential expression by comparing thefluorescence profile on the grids at different dilutions among differentlibraries (representing differential screening probes). For example:

Library A, Ditags Diluted 1:10 A B C D E 1 FL 2 FL 3 FL FL 4 FL 5 FLLibrary B, Ditags Diluted 1:10 A B C D E 1 FL 2 FL FL 3 FL FL 4 5 FL FLLibrary A, Ditags Diluted 1:50 A B C D E 1 FL 2 3 FL 4 FL 5 FL LibraryB, Ditags Diluted 1:50 A B C D E 1 FL 2 FL 3 FL FL 4 5 Library A, DitagsDiluted 1:100 A B C D E 1 FL 2 3 FL 4 FL 5 FL Library B, Ditags Diluted1:100 A B C D E 1 FL 2 FL 3 FL 4 5

The individual oligonucleotides thus hybridize to ditags with thefollowing characteristics:

TABLE 3 1.10 1:50 1.100 Dilution Lib A Lib B Lib A Lib B Lib A Lib B1A + + + + + + 2C + + + 2E + + 3B + + + + + + 3C + + + 4D + + +5A + + + + 5E +

Table 3 summarizes the results of the differential hybridization. Tagshybridizing to 1A and 3B reflect highly abundant mRNAs that are notdifferentially expressed (since the tags hybridize to both libraries atall dilutions); tag 2C identifies a highly abundant mRNA, but only inLibrary B. 2E reflects a low abundance transcript (since it is onlydetected at the lowest dilution) that is not found to be differentiallyexpressed; 3C reflects a moderately abundant transcript (since it isexpressed at the lower two dilutions) in Library B that is expressed atlow abundance in Library A. 4D reflects a differentially-expressed, highabundance transcript restricted to Library A; 5A reflects a transcriptthat is expressed at high abundance in Library A but only at lowabundance in Library B; and 5E reflects a differentially-expressedtranscript that is detectable only in Library B.

In another PSA embodiment, step 3 above does not involve the use of afluorescent or other identifier; instead, at the last round ofamplification of the ditags, labeled dNTPs are used so that aftermelting, half of all molecules are labeled and can serve as probes forhybridization to oligonucleotides fixed on the chips.

In yet another PSA embodiment, instead of ditags, a particular portionof the transcript is used, e.g., the sequence between the 3′ terminus ofthe transcript and the first anchoring enzyme site. In that particularcase, a double-stranded cDNA reverse transcript is generated asdescribed in the Detailed Description. The transcripts are cut with theanchoring enzyme, a linker is added containing a PCR primer andamplification is initiated (using the primer at one end and the poly Atail at the other) while the transcripts are still on the strepavidinbead. At the last round of amplification, fluoresceinated dNTPs are usedso that half of the molecules are labeled. The linker-primer can beoptionally removed by use of the anchoring enzyme at this point in orderto reduce the size of the fragments. The soluble fragments are thenmelted and captured on solid matrices containing CATGOOOOOOOOOO, as inthe previous example. Analysis and scoring (only of the half of thefragments which contain fluoresceinated bases) is as described above.

For use in clonal sequencing, ditags or concatemers would be diluted andadded to wells of multiwell plates, for example, or other receptacles sothat on average the wells would contain, statistically, less than oneDNA molecule per well (as is done in limited dilution for cell cloning).Each well would then receive reagents for PCR or another amplificationprocess and the DNA in each receptacle would be sequenced, e.g., by massspectroscopy. The results will either be a single sequence (there havingbeen a single sequence in that receptacle), a “null” sequence (no DNApresent) or a double sequence (more than one DNA molecule), which wouldbe eliminated from consideration during data analysis. Thereafter,assessment of differential expression would be the same as describedherein.

These results demonstrate that SAGE provides both quantitative andqualitative data about gene expression. The use of different anchoringenzymes and/or tagging enzymes with various recognition elements lendsgreat flexibility to this strategy. In particular, since differentanchoring enzymes cleave cDNA at different sites, the use of at least 2different Aes on different samples of the same cDNA preparation allowsconfirmation of results and analysis of sequences that might not containa recognition site for one of the enzymes.

As efforts to fully characterize the genome near completion, SAGE shouldallow a direct readout of expression in any given cell type or tissue.In the interim, a major application of SAGE will be the comparison ofgene expression patterns in among tissues and in various developmentaland disease states in a given cell or tissue. One of skill in the artwith the capability to perform PCR and manual sequencing could performSAGE for this purpose. Adaptation of this technique to an automatedsequencer would allow the analysis of over 1,000 transcripts in a single3 hour run. An ABI 377 sequencer can produce a 451 bp readout for 36templates in a 3 hour run (451 bp/11 bp per tag×36=1476 tags). Theappropriate number of tags to be determined will depend on theapplication. For example, the definition of genes expressed atrelatively high levels (0.5% or more) in one tissue, but low in another,would require only a single day. Determination of transcripts expressedat greater than 100 mRNA's per cell (0.025% or more) should bequantifiable within a few months by a single investigator. Use of twodifferent Anchoring Enzymes will ensure that virtually all transcriptsof the desired abundance will be identified. The genes encoding thosetags found to be most interesting on the basis of their differentialrepresentation can be positively identified by a combination ofdata-base searching, hybridization, and sequence analysis asdemonstrated in Table 2. Obviously, SAGE could also be applied to theanalysis of organisms other than humans, and could direct investigationtowards genes expressed in specific biologic states.

SAGE, as described herein, allows comparison of expression of numerousgenes among tissues or among different states of development of the sametissue, or between pathologic tissue and its normal counterpart. Suchanalysis is useful for identifying therapeutically, diagnostically andprognostically relevant genes, for example. Among the many utilities forSAGE technology, is the identification of appropriate antisense ortriple helix reagents which may be therapeutically useful. Further, genetherapy candidates can also be identified by the SAGE technology. Otheruses include diagnostic applications for identification of individualgenes or groups of genes whose expression is shown to correlate topredisposition to disease, the presence of disease, and prognosis ofdisease, for example. An abundance profile, such as that depicted inTable 1, is useful for the above described applications. SAGE is alsouseful for detection of an organism (e.g., a pathogen) in a host ordetection of infection-specific genes expressed by a pathogen in a host.

The ability to identify a large number of expressed genes in a shortperiod of time, as described by SAGE in the present invention, providesunlimited uses.

Although the invention has been described with reference to thepresently preferred embodiment, it should be understood that variousmodifications can be made without departing from the spirit of theinvention. Accordingly, the invention is limited only by the followingclaims.

                   #             SEQUENCE LISTING<160> NUMBER OF SEQ ID NOS: 41 <210> SEQ ID NO 1 <211> LENGTH: 43<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 1ttttaccagc ttattcaatt cggtcctctc gcacagggac atg     #                  # 43 <210> SEQ ID NO 2 <211> LENGTH: 36 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 2atggtcgaat aagttaagcc aggagagcgt gtccct       #                  #       36 <210> SEQ ID NO 3 <211> LENGTH: 44 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 3tttttgtaga cattctagta tctcgtcaag tcggaaggga catg    #                  # 44 <210> SEQ ID NO 4 <211> LENGTH: 37 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 4aacatctgta agatcataga gcagttcagc cttccct       #                  #      37 <210> SEQ ID NO 5 <211> LENGTH: 21 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 5ccagcttatt caattcggtc c            #                  #                   #21 <210> SEQ ID NO 6 <211> LENGTH: 21<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 6gtagacattc tagtatctcg t            #                  #                   #21 <210> SEQ ID NO 7 <211> LENGTH: 26<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 7gacgtcgacc tgaggtaatt ataacc           #                  #              26 <210> SEQ ID NO 8 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 8 gagcacacc                #                   #                   #          9 <210> SEQ ID NO 9<211> LENGTH: 9 <212> TYPE: DNA <213> ORGANISM: Homo sapiens<400> SEQUENCE: 9 ttctgtgtg                 #                  #                   #          9 <210> SEQ ID NO 10 <211> LENGTH: 9<212> TYPE: DNA <213> ORGANISM: Homo sapiens <400> SEQUENCE: 10gaacacaaa                 #                   #                  #          9 <210> SEQ ID NO 11 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 11tcagggtga                 #                   #                  #          9 <210> SEQ ID NO 12 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 12gcgtgacca                 #                   #                  #          9 <210> SEQ ID NO 13 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 13gtgtgtgct                 #                   #                  #          9 <210> SEQ ID NO 14 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 14tcattggcc                 #                   #                  #          9 <210> SEQ ID NO 15 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 15ccagagagt                 #                   #                  #          9 <210> SEQ ID NO 16 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 16tcctcaaaa                 #                   #                  #          9 <210> SEQ ID NO 17 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 17agccttggt                 #                   #                  #          9 <210> SEQ ID NO 18 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 18gtgtgcgct                 #                   #                  #          9 <210> SEQ ID NO 19 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 19tgcgagacc                 #                   #                  #          9 <210> SEQ ID NO 20 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 20gtgaaaccc                 #                   #                  #          9 <210> SEQ ID NO 21 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 21ggtgactct                 #                   #                  #          9 <210> SEQ ID NO 22 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 22aaggtaaca                 #                   #                  #          9 <210> SEQ ID NO 23 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 23tcccctgtg                 #                   #                  #          9 <210> SEQ ID NO 24 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 24gtgaccacg                 #                   #                  #          9 <210> SEQ ID NO 25 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 25cctgtaatc                 #                   #                  #          9 <210> SEQ ID NO 26 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 26cacgttgga                 #                   #                  #          9 <210> SEQ ID NO 27 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 27agccctaca                 #                   #                  #          9 <210> SEQ ID NO 28 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 28agcacctcc                 #                   #                  #          9 <210> SEQ ID NO 29 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 29acgcaggga                 #                   #                  #          9 <210> SEQ ID NO 30 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 30aattgaaga                 #                   #                  #          9 <210> SEQ ID NO 31 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 31ttctgtggg                 #                   #                  #          9 <210> SEQ ID NO 32 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 32ttcatacac                 #                   #                  #          9 <210> SEQ ID NO 33 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 33gtggcaggc                 #                   #                  #          9 <210> SEQ ID NO 34 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 34gtaaaaccc                 #                   #                  #          9 <210> SEQ ID NO 35 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 35gaacacaca                 #                   #                  #          9 <210> SEQ ID NO 36 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 36cctgggaag                 #                   #                  #          9 <210> SEQ ID NO 37 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 37cccatcgtc                 #                   #                  #          9 <210> SEQ ID NO 38 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 38tcctcaaaa                 #                   #                  #          9 <210> SEQ ID NO 39 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 39tgcgagacc                 #                   #                  #          9 <210> SEQ ID NO 40 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 40acgcaggga                 #                   #                  #          9 <210> SEQ ID NO 41 <211> LENGTH: 9 <212> TYPE: DNA<213> ORGANISM: Homo sapiens <400> SEQUENCE: 41aattgaaga                 #                   #                  #          9

What is claimed is:
 1. A method for making a tag which identifies acomplementary deoxyribonucleic acid (cDNA) oligonucleotide, comprising:providing a complementary deoxyribonucleic acid (cDNA) oligonucleotidecomprising a 5′ and a 3′ and; cleaving said cDNA oligonucleotide with arestriction enzyme at a first restriction endonuclease site to providecDNA fragments; isolating the 5′ or 3′ end of said cDNA oligonucleotide;linking an oligonucleotide linker to an isolated cDNA fragmentcomprising the 5′ or 3′ end of said cDNA oligonucleotide, wherein theoligonucleotide linker comprises a recognition site for a secondrestriction endonuclease enzyme which cleaves at a site distant from therecognition site; and cleaving the isolated cDNA fragment with thesecond restriction endonuclease enzyme to provide a tag which identifiesa cDNA oligonucleotide.
 2. The method of claim 1 wherein the secondrestriction endonuclease is a type IIS endonuclease.
 3. The method ofclaim 2 wherein the type IIS endonuclease is selected from the groupconsisting of BsmFI and FokI.
 4. A method for making a defined sequencetag which identifies a complementary deoxyribonucleic acid (cDNA)oligonucleotide, comprising the steps of: cleaving a cDNA sample with afirst restriction endonuclease, wherein the endonuclease cleaves thecDNA at a defined position relative to the 5′ or 3′ terminus of the cDNAthereby producing defined sequence tags; isolating the defined sequencetags; ligating an oligonucleotide linker to the defined sequence tags,wherein the oligonucleotide linker comprises a recognition site for asecond restriction endonuclease which cleaves at a site outside of itsrecognition sequence; cleaving the defined sequence tags with the secondrestriction endonuclease at the site outside of its recognition sequenceto provide defined sequence tags having a defined length.
 5. The methodof claim 4, wherein the first restriction enzyme has a four base pairrecognition site.
 6. The method of claim 5 wherein the first restrictionendonuclease is NlaIII.
 7. The method of claim 4 wherein the cDNAcomprises a means for capture.
 8. The method of claim 7 wherein themeans for capture is a binding element.
 9. The method of claim 8 whereinthe binding element is biotin.
 10. The method of claim 4 wherein thesecond restriction endonuclease is a type IIS endonuclease.
 11. Themethod of claim 10 wherein the type IIS endonuclease is selected fromthe group consisting of BsmFI and FokI.